Amid growing global scrutiny of Indian-made drugs, the central government has become the sole authority to issue manufacturing licences for new drugs for export, taking back the power from state governments.

- From now on the sole licensing authority will be the Central Drugs Standard Control Organization (CDSCO), India's apex drug regulatory body.
About CDSCO:
- The Central Drugs Standard Control Organisation (CDSCO) is the apex regulatory body for the medical device industry in India under the Drugs and Cosmetics Act.
- The CDSCO works under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India.
Key Responsibilities of CDSCO:
- Approval of new drugs: CDSCO grants permission for the production and commercialization of new drugs in India.
- Conduct of clinical trials: CDSCO regulates and monitors clinical trials conducted in India to ensure the safety and rights of participants.
- Laying down the standards for drugs: CDSCO sets the standards for the quality, safety, and efficacy of drugs manufactured, imported, or sold in India.
- Control over the quality of imported drugs: CDSCO ensures that imported drugs meet the same standards as domestically produced drugs.
- Coordination of the activities of State Drug Control Organizations: CDSCO coordinates with State Drug Control Organizations to ensure uniform implementation of drug regulations across the country.
- Inspection and audits: CDSCO conducts inspections and audits of drug manufacturing facilities and laboratories to ensure compliance with regulations.
- Drug Controller General of India (DCGI): The DCGI is the head of the CDSCO and is responsible for its overall functioning.
- Headquarters: CDSCO is headquartered in New Delhi, India.
Joint Responsibility with State Regulators:
- CDSCO, along with state regulators, is jointly responsible for granting licenses for certain specialized categories of critical drugs such as blood and blood products, I. V. Fluids, vaccines, and sera.